For the estimated 54 million Americans with obstructive sleep apnea, bedtime isn't refreshing. Their airways are partially blocked during sleep, leading to daytime grogginess and lasting health ...

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative ...

Offering strong upside potential, LivaNova PLC (NASDAQ:LIVN) earns a spot on our list of the 10 Most Undervalued Foreign ...

The Samsung Galaxy Watch 8 Classic smartwatch justifies its expensive price with a premium build featuring a rotating bezel, ...

Pharmaceutical company Apnimed says it's getting positive results from the clinical trials for an oral pill that could treat sleep apnea. It's taken before bedtime to help keep airways open during ...

Poor sleep can leave people feeling exhausted, irritable and unfocused during the day. And if left untreated, sleep apnea can increase the risk for serious conditions such as high blood pressure ...

Apnimed has scored another phase 3 knockout. | Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the number of nightly ...

Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with obstructive sleep apnea (OSA).

The Samsung Galaxy Watch 8 has only minor physical changes from its predecessor, but new AI abilities help it take a ...

Obstructive sleep apnea is still largely undiagnosed and untreated. In a growing marketplace of solutions, can negative pressure devices compete?